SEC Form 4 · accession 0001610717-26-000385
Neumora Therapeutics, Inc. · NMRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daljit Singh Aurora
Officer — See Remarks
Period of report
Aug 20, 2026
Accepted (ET)
Aug 21, 2026 · 7:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001885522
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 20, 2026 | M | 67,741 | $0.72 | A | 116,491 | D | |
| Common StockF1 | Aug 20, 2026 | S | 67,741 | $1.5144 | D | 48,750 | D | |
| Common StockF3 | Aug 20, 2026 | M | 21,685 | $0.72 | A | 21,685 | I | See footnote |
| Common StockF3 | Aug 20, 2026 | M | 45,026 | $0.72 | A | 66,711 | I | See footnote |
| Common StockF2,F3 | Aug 20, 2026 | S | 66,711 | $1.514 | D | 0 | I | See footnote |
| Common Stock | Aug 21, 2026 | M | 20,553 | $0.72 | A | 69,303 | D | |
| Common StockF7 | Aug 21, 2026 | S | 20,553 | $1.5949 | D | 48,750 | D | |
| Common StockF3 | Aug 21, 2026 | M | 21,055 | $0.72 | A | 21,055 | I | See footnote |
| Common StockF8,F3 | Aug 21, 2026 | S | 21,055 | $1.5958 | D | 0 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $0.72 | Aug 20, 2026 | M | 67,741 | D | — | Feb 14, 2034 | Common Stock | 67,741 | 109,527 | D |
| Stock Option (Right to Buy)F3,F5 | $0.72 | Aug 20, 2026 | M | 45,026 | D | — | Jan 19, 2033 | Common Stock | 45,026 | 0 | I |
| Stock Option (Right to Buy)F3,F5 | $0.72 | Aug 20, 2026 | M | 21,685 | D | — | Sep 20, 2031 | Common Stock | 21,685 | 115,853 | I |
| Stock Option (Right to Buy)F6 | $1.52 | Aug 20, 2026 | A | 200,000 | A | — | Aug 20, 2036 | Common Stock | 200,000 | 200,000 | D |
| Stock Option (Right to Buy)F4 | $0.72 | Aug 21, 2026 | M | 20,553 | D | — | Feb 14, 2034 | Common Stock | 20,553 | 88,974 | D |
| Stock Option (Right to Buy)F3,F5 | $0.72 | Aug 21, 2026 | M | 21,055 | D | — | Sep 20, 2031 | Common Stock | 21,055 | 94,798 | I |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $1.485 to $1.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F2This transaction was executed in multiple trades at prices ranging from $1.48 to $1.6252, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
- F425% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- F5The stock option is fully vested and exercisable.
- F625% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- F7This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6379, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8This transaction was executed in multiple trades at prices ranging from $1.51 to $1.6393, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks
Title: Chief Operating and Development Officer